INVIVYD, INC. Lessor, Operating Lease, Payment to be Received, Year One
INVIVYD, INC. (IVVD) had Lessor, Operating Lease, Payment to be Received, Year One of $1.40 million as of 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Leases
us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths · last filed 2024-03-28
- 2023-12-31: Lessor, Operating Lease, Payment to be Received, Year One $1.40M.
- 2022-12-31: Lessor, Operating Lease, Payment to be Received, Year One $1.50M.
- 2022-09-30: Lessor, Operating Lease, Payment to be Received, Year One $300.00K.
- 2022-06-30: Lessor, Operating Lease, Payment to be Received, Year One $1.00M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year One |
|---|---|
| 2023-12-31 | $1.40M 10-K · filed 2024-03-28 |
| 2022-12-31 | $1.50M 8-K · filed 2024-02-09 |
| 2022-09-30 | $300.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |